#7 This thread has not aged particularly well Given the recent spate of case reports describing residual gastric contents in context of fasted patients on semaglutide and the recent ASA consensus document etc, I'm curious what approach centers are taking to the perioperative mgmt of GLP-1 receptor agonists like semaglutide
INJECTIONS All services are cash pay but you may file with your insurance on your own
US operations
extended release version approved in 2017 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
These medications are generally intended to: Help you feel full longer Help reduce cravings Help improve blood sugar control Help support significant, sustained weight loss in qualified patients When prescribed and monitored by a primary care provider, GLP-1 medications can be a helpful tool in a thorough, medically supervised weight loss program
MD, Johannes FE, Mann MD, Nauck MA, Steven MD, Nissen E, Pocock MDS, Neil PD, Poulter R, Lasse FMS, Ravn S, Steinberg MDPDWM, Mette Stockner MD, Bernard Zinman MD, Bergenstal MDRM, M.D., and, Buse JB
